Drugdocs | Maribavir

Drug updated on 3/28/2024

Dosage Form	Tablet (oral; 200 mg)
Drug Class	Kinase inhibitors
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Maribavir (Livtencity) is used for the treatment of adults and pediatric patients who are 12 years or older, weighing at least 35 kg, with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.
The information about Livtencity was derived from a systematic review/meta-analysis document. A total of one such document was reviewed in this process.
This meta-analysis included fifteen randomized controlled trials investigating different antiviral agents for CMV prophylaxis in allogeneic hematopoietic cell transplantation. These trials involved seven different antiviral agents including maribavir (Livtencity).
According to the findings from these studies, there's evidence that CMV disease and infection can be significantly reduced by using an antiviral prophylaxis like maribavir. However, it did not show any significant influence on reducing death risk compared to other drugs studied.
In terms of safety comparison among various drugs studied in these trials; letermovir appeared as the safest option followed by acyclovir while both were found safer than ganciclovor which also includes maribavair under study.
Despite its effectiveness against CMV infections/diseases post-transplantation shown through these studies; further head-to-head comparisons are needed to evaluate definitive efficacy and safety profile of Maribavair(Livetincity).

Document Title	Year	Source
Livtencity (maribavir) Prescribing Information.	2023	Takeda Pharmaceuticals America Inc., Lexington, MA

Document Title	Year	Source
Clinical and pharmacoeconomic combined report.	2023	CADTH
Assessment report: Livtencity.	2022	EMA
Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.	2018	Transplantation and Cellular Therapy

Document Title	Year	Source
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).	2019	The Lancet: Infectious Diseases